Combining c-Abl-specific tyrosine kinase inhibitors (TKIs) with tigecycline emerges as a promising strategy for chronic myeloid leukemia (CML) treatment. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.